



Construction will soon commence on the Ribonucleic Acid (RNA) Research and Pilot Manufacturing Facility at Macquarie University's Wallumattagal Campus. The NSW Government has committed \$96 million for the facility, with a further \$119 million announced over 10 years for RNA research and development initiatives.

Planning approval has been granted by the Department of Planning, Housing and Infrastructure and the construction contract awarded to Hindmarsh Construction, who will commence on site in the coming months. The new facility will be located in the Connect Innovation Precinct at Macquarie University and operated by Myeloid Therapeutics, a global therapeutics company.

The project is being delivered by Health Infrastructure, on behalf of the Office of the Chief Scientist and Engineer.

Benefits

The project will:

- be the first opportunity for RNA research and development to be tested and developed locally, across the broad spectrum of RNA technology, reducing Australia's reliance on international supply.
- provide Australian patients with faster access to new and innovative RNA therapeutics to treat diseases such as cancer and rare genetic diseases.
- attract global industry investment to Australia, foster local jobs and skills and secure domestic-market access to future therapeutics.
- be central to NSW's thriving RNA research and development ecosystem, surrounded by medical and research facilities, existing infrastructure, and world-leading RNA and cell and gene therapy expertise.

- boost innovation and technology in NSW, centralise RNA knowledge and expertise, create highly skilled jobs, and help NSW become a global leader in RNA research and production.
- capitalise on NSW's competitive advantage by translating its strengths in research and development into a sustainable commercial pipeline of RNA therapeutics and products.
- protect our livestock industry by supporting the production of vaccines and other treatments against animal diseases that could affect agricultural industries and the economy.

Fast Facts

Funding: \$96 million and an additional \$119 million for research and development

Project Sponsor: Office of the Chief Scientist and Engineer


Current status: Under construction

Location: Macquarie Park (Macquarie University)

Expected construction completion: Early to mid 2026

Operator: Myeloid Therapeutics

Milestones



Frequently asked questions

What will the new facility include?

The new facility, which will include cleanrooms, laboratories and other support spaces, will be the only site in Australia where a wide range of new and existing RNA therapeutics will be produced. Therapies will include vaccines as well as treatments for rare diseases in both people and animals.

Why do we need an RNA research and pilot manufacturing facility?


The RNA Research and Pilot Manufacturing Facility will reduce Australia's reliance on international supply and provide patients with faster access to new therapies for hard-to-treat diseases such as cancer and rare genetic disorders. There is also potential to attract global investment to Australia and increase the number of local jobs.

Where will the facility be located?

The facility will be located at Macquarie University's Wallumattagal Campus, on the corner of Culloden and Gymnasium Roads in the Connect Macquarie Park Innovation District. The district is one of Australia's leading science innovation hubs or areas, with access to world-class medical research, health services, medical manufacturing expertise, intellectual property and infrastructure.

When will construction start?

Construction is expected to start in the coming months, once the building contractor is established on site.



When will works occur?

Construction will take place during standard construction hours of 7am to 6pm, Monday to Friday and between 8am and 1pm Saturdays. Limited work may occur out of hours, for example on Sundays or during the evening or early morning when required. Neighbours will be notified in advance of any out of hours works required.

How will noise and dust be managed?

Health Infrastructure is committed to ensuring work is completed safely and efficiently and with minimal impact to the community. The site will be subject to air quality monitoring, and noise and dust will be appropriately managed throughout construction in accordance with the planning approval. Noise will be kept to a minimum as best as possible during the construction period.

When will the RNA Research and Pilot Manufacturing Facility open?

The facility is expected to be operational in 2026.

How can I contact the project team?

If you have any questions or would like more information, please contact our project team via hi-rna@health.nsw.gov.au. For an interpreter, call **131 450** and ask them to call **02 9978 5402**.